X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cefazolin - therapeutic use (1310) 1310
index medicus (1243) 1243
humans (1178) 1178
female (777) 777
male (707) 707
middle aged (527) 527
anti-bacterial agents - therapeutic use (524) 524
adult (495) 495
aged (390) 390
cephalosporins - therapeutic use (290) 290
surgical wound infection - prevention & control (285) 285
abridged index medicus (273) 273
cefazolin - administration & dosage (232) 232
surgery (213) 213
prospective studies (200) 200
adolescent (181) 181
animals (180) 180
antibiotic prophylaxis (176) 176
premedication (170) 170
staphylococcal infections - drug therapy (147) 147
gentamicins - therapeutic use (139) 139
antibiotics (134) 134
drug therapy, combination (134) 134
treatment outcome (131) 131
cefazolin (128) 128
retrospective studies (127) 127
double-blind method (126) 126
vancomycin - therapeutic use (120) 120
aged, 80 and over (117) 117
clinical trials as topic (113) 113
postoperative complications - prevention & control (113) 113
microbial sensitivity tests (109) 109
risk factors (108) 108
child (107) 107
bacterial infections - prevention & control (99) 99
random allocation (95) 95
infectious diseases (92) 92
bacterial infections - drug therapy (91) 91
ophthalmology (90) 90
time factors (89) 89
cefazolin - adverse effects (88) 88
infections (88) 88
anti-bacterial agents - administration & dosage (85) 85
pharmacology & pharmacy (82) 82
microbiology (81) 81
pregnancy (78) 78
cefazolin - pharmacology (73) 73
health aspects (73) 73
ampicillin - therapeutic use (70) 70
staphylococcal infections - microbiology (70) 70
eye infections, bacterial - drug therapy (69) 69
tobramycin - therapeutic use (68) 68
child, preschool (67) 67
infection (66) 66
injections, intravenous (64) 64
staphylococcus aureus (62) 62
medicine, general & internal (60) 60
drug therapy, combination - therapeutic use (59) 59
drug administration schedule (58) 58
infant (58) 58
surgical wound infection - epidemiology (58) 58
staphylococcal infections - prevention & control (57) 57
staphylococcus aureus - drug effects (57) 57
orthopedics (56) 56
prevention (56) 56
cefazolin - pharmacokinetics (55) 55
urology & nephrology (55) 55
corneal ulcer - drug therapy (54) 54
clindamycin - therapeutic use (53) 53
staphylococcus aureus - isolation & purification (52) 52
antibiotic prophylaxis - methods (50) 50
cefazolin - blood (50) 50
penicillins - therapeutic use (50) 50
ceftriaxone - therapeutic use (49) 49
surgical wound infection - microbiology (49) 49
peritonitis - drug therapy (48) 48
rabbits (48) 48
urinary tract infections - drug therapy (48) 48
drug resistance, microbial (47) 47
follow-up studies (46) 46
prophylaxis (46) 46
cefamandole - therapeutic use (45) 45
cefotaxime - therapeutic use (45) 45
obstetrics & gynecology (45) 45
vancomycin (45) 45
antibiotic-prophylaxis (44) 44
eye infections, bacterial - microbiology (44) 44
young adult (44) 44
drug evaluation (43) 43
infant, newborn (41) 41
risk (41) 41
cephalosporins - administration & dosage (40) 40
streptococcal infections - drug therapy (40) 40
surgical wound infection - etiology (40) 40
cephalothin - therapeutic use (39) 39
corneal ulcer - microbiology (39) 39
metronidazole - therapeutic use (39) 39
ciprofloxacin - therapeutic use (38) 38
pediatrics (38) 38
anti-infective agents - therapeutic use (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1135) 1135
Japanese (41) 41
French (38) 38
German (30) 30
Russian (25) 25
Italian (19) 19
Spanish (17) 17
Chinese (8) 8
Bulgarian (6) 6
Portuguese (5) 5
Czech (3) 3
Hebrew (2) 2
Polish (2) 2
Danish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Spine, ISSN 0362-2436, 04/2013, Volume 38, Issue 7, pp. 609 - 616
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, pp. e37281 - e37281
Formation of resilient biofilms on medical devices colonized by pathogenic microorganisms is a major cause of health-care associated infection. While in vitro... 
ANTIBIOTIC-LOCK TECHNIQUE | CONTROLLED-TRIAL | DIAGNOSIS | THERAPY | BACTEREMIA | IN-VIVO | BIOLOGY | ACCESS SYSTEM | MICE | CANCER | BLOOD-STREAM INFECTIONS | Staphylococcal Infections - drug therapy | Cefazolin - therapeutic use | Gentamicins - therapeutic use | Biofilms - growth & development | Pseudomonas Infections - complications | Rats | Male | Equipment Contamination | Staphylococcal Infections - complications | Anti-Bacterial Agents - therapeutic use | Animals | Staphylococcus epidermidis | Immunosuppression - adverse effects | Catheters, Indwelling - adverse effects | Models, Animal | Pseudomonas aeruginosa | Catheterization, Central Venous - adverse effects | Escherichia coli Infections - complications | Medical research | Medical equipment | Bacterial infections | Escherichia coli | Staphylococcus aureus infections | Medicine, Experimental | Cross infection | Nosocomial infections | Health aspects | Physiological apparatus | Staphylococcus aureus | Pediatrics | Surgical implants | Bioluminescence | Disseminated infection | Clinical trials | Infections | Microorganisms | E coli | Bacteria | Pathogens | Medical devices | Stability | Complications | Medical instruments | Staphylococcus infections | Disease control | Contamination | Catheters | Biofilms | Antibiotics | Colonization | Index Medicus | Cefazolin/therapeutic use | Escherichia coli infections | Biofilms/growth & development | Central Venous/adverse effects | Life Sciences | Staphylococcal Infections/complications/drug therapy | Pseudomonas Infections/complications | Bloodstream infections | Immunosuppression/adverse effects | Bacterial biofilms | Gentamicins/therapeutic use | Catheterization | Indwelling/adverse effects | Escherichia coli Infections/complications | bacterial pathogens | Bacteriology | Microbiology and Parasitology | Animal | Models | Anti-Bacterial Agents/therapeutic use
Journal Article
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2011, Volume 69, Issue 8, pp. 2106 - 2111
Purpose In 2009, the American Academy Of Orthopedic Surgeons recommended lifelong prophylaxis after orthopedic total joint replacement (TJR) before these... 
Surgery | KNEE REPLACEMENT | BACTEREMIA | DENTISTRY, ORAL SURGERY & MEDICINE | ARTHROPLASTY | DENTAL TREATMENT | INFECTION | ENDOCARDITIS | PROSTHETIC JOINTS | HIP | Staphylococcus epidermidis - physiology | Antibiotic Prophylaxis - statistics & numerical data | Disinfection - statistics & numerical data | Humans | Joint Prosthesis - statistics & numerical data | Peroxides - therapeutic use | Pseudomonas aeruginosa - physiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Povidone-Iodine - therapeutic use | Retrospective Studies | Temporomandibular Joint - surgery | Surgical Wound Infection - epidemiology | Cefazolin - therapeutic use | Gentamicins - therapeutic use | Penicillins - therapeutic use | Peptostreptococcus - physiology | Arthroplasty, Replacement - statistics & numerical data | Bacitracin - therapeutic use | Clindamycin - therapeutic use | Gram-Positive Bacterial Infections - epidemiology | Practice Patterns, Dentists' - statistics & numerical data | Biofilms | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Device Removal - statistics & numerical data | Vancomycin - therapeutic use | Practice Guidelines as Topic | Therapeutic Irrigation | Surveys | Usage | Joint replacement | Antibiotics | Index Medicus | Abridged Index Medicus | Dentistry
Journal Article
Trials, ISSN 1745-6215, 2016, Volume 17, Issue 1, pp. 170 - 170
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a serious infection resulting in 20-50 % 90 day mortality. The limitations of... 
Flucloxacillin | Cefazolin | Methicillin-resistant | Combination | Daptomycin | MRSA | Randomised controlled trial | Vancomycin | Cloxacillin | Staphylococcus aureus | Nafcillin | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | ACUTE KIDNEY INJURY | VITRO PHARMACOKINETIC/PHARMACODYNAMIC MODEL | PIPERACILLIN-TAZOBACTAM | INTRAVENOUS-DRUG-USERS | EMPIRICAL-THERAPY | IN-VITRO | ANTIBACTERIAL ACTIVITY | PLUS CEFTAROLINE | BETA-LACTAMS | Singapore | Humans | Clinical Protocols | Anti-Bacterial Agents - therapeutic use | Methicillin-Resistant Staphylococcus aureus - pathogenicity | Time Factors | Anti-Bacterial Agents - adverse effects | Staphylococcal Infections - microbiology | Drug Therapy, Combination | Methicillin Resistance | Cloxacillin - therapeutic use | Daptomycin - therapeutic use | Staphylococcal Infections - drug therapy | Cefazolin - therapeutic use | Methicillin-Resistant Staphylococcus aureus - drug effects | Treatment Outcome | Floxacillin - therapeutic use | New Zealand | Staphylococcal Infections - diagnosis | Vancomycin - therapeutic use | beta-Lactams - adverse effects | Israel | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Australia | beta-Lactams - therapeutic use | Research Design | Prevention | Drug resistance in microorganisms | Care and treatment | Analysis | Staphylococcus aureus infections | Clinical trials | Development and progression | Beta lactamases | Research | Health aspects | Index Medicus
Journal Article
JAMA Surgery, ISSN 2168-6254, 05/2016, Volume 151, Issue 5, pp. 432 - 439
Journal Article
Journal Article